赛诺菲喜保宁购买途径和价格

It is an anti-epileptic drug and is clinically used to treat epilepsy in which other anti-epileptic drugs are ineffective, especially partial seizures. It can also treat infantile spasms (West syndrome, West syndrome). Vigabatrin's generic name is vigabatrin and its brand name is Sabril. It is a drug used to treat epilepsy and infantile spasms. It was developed in the 1980s. The treatment was approved in the UK in 1989. On August 21, 2009, the U.S. FDA approved Sabril as a monotherapy for pediatric patients 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjunctive (additional) treatment for adult patients with refractory complex partial epilepsy (CPS). Vigabatrin is a synthetic derivative of gamma-aminobutyric acid (GABA), which increases the concentration of the inhibitory neurotransmitter GABA in the brain by irreversibly inhibiting GABA aminotransferase. It can increase the level of GABA in the human brain as the activity of GABA aminotransferase continues to decrease rapidly, and there is an obvious dose-effect relationship. Studies have shown that after administration of this drug, the concentration of GABA in the brains of rodents and in the cerebrospinal fluid of humans increases, and the degree of increase is related to the dose.

Sanofi (NYSE: SNY) was founded in 1973. Its predecessor was Sanofi-Aventis. It was changed to its current name: Sanofi in May 2011. It is headquartered in Paris, France, and has 113,496 full-time employees in more than 100 countries around the world. It is the world's leading diversified pharmaceutical and health company with diversified products, including drugs, vaccines and innovative treatment solutions. The specification of Sanofi Vigabatrin is 500mg*100 capsules/box, priced at approximately RMB 1,450, and is suitable for long-term use by patients. Sanofi can be obtained through domestic professional overseas medical service institutions.

Recommended related hot articles: /newsDetail/97426.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.